Editas Medicine, Inc. (EDIT)
32.14 -0.66 (-2.01%)
After hours: 4:11PM EDT
Chart Events
Performance Outlook
| Previous Close | 31.29 |
| Open | 29.70 |
| Bid | 32.69 x 1200 |
| Ask | 32.70 x 800 |
| Day's Range | 29.35 - 33.35 |
| 52 Week Range | 23.51 - 99.95 |
| Volume | 1,754,779 |
| Avg. Volume | 1,900,168 |
| Market Cap | 2.225B |
| Beta (5Y Monthly) | 1.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.20 |
| Earnings Date | Aug 05, 2021 - Aug 10, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 47.33 |
Fair Value
Related Research
- Daily – Vickers Top Buyers & Sellers for 03/08/2021
- Daily – Vickers Top Buyers & Sellers for 03/05/2021
- Investor's Business Daily
11 Plunging Stocks Are Badly Burning Cathie Wood's ARK Invest
Cathie Wood's ARK Invest is still red-hot, but now in the opposite way: It's getting burned by many collapsing stocks including some in the S&P 500.
- Motley Fool
Editas Medicine, Inc. (EDIT) Q1 2021 Earnings Call Transcript
Earlier this morning, we issued a press release providing our financial results and corporate updates for the first quarter of 2021. As a reminder, various remarks that we make during this call about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent annual report on Form 10-K, which is on file with the SEC.
- Motley Fool
What Really Mattered With Editas Medicine's Q1 Update
Editas Medicine (NASDAQ: EDIT) entered 2021 with tremendous momentum. The company announced a Q1 net loss of $56.7 million, or $0.86 per share, based on generally accepted accounting principles (GAAP). In the prior-year period, Editas posted a GAAP net loss of $37.7 million, or $0.69 per share.
